# Biotech Daily Digest ‚Äî 2025-11-05

**55 items from 3 sources**

## Summary by Source

- Endpoints News: 8 items
- Fierce Biotech: 15 items
- arXiv q-bio: 32 items


## Endpoints News

- **[Centessa says early data for narcolepsy drug support registrational plans](https://endpoints.news/centessa-says-early-data-for-narcolepsy-drug-support-registrational-plans/)**  
  _Wed, 05 Nov 2025 12:00:41 +0000_  
  Centessa Pharmaceuticals shared Phase 2a data for its lead orexin agonist that‚Äôs being studied in a variety of sleep disorders, and the results, while from a small cohort, suggest it could match the efficacy of ...

- **[Cardio biotech Braveheart gets $185M, names Biogen CEO as its chair](https://endpoints.news/cardio-biotech-braveheart-gets-185m-names-biogen-ceo-as-its-chair/)**  
  _Wed, 05 Nov 2025 11:00:13 +0000_  
  Braveheart Bio has collected $185 million from leading biotech investors to start registration-enabling studies for a cardiovascular drug it licensed from Hengrui, one of the biggest drug developers in China.



 The biotech will use the ...

- **[Novo Nordisk sales miss underlines its need for Metsera](https://endpoints.news/novo-nordisk-sales-miss-underlines-its-need-for-metsera/)**  
  _Wed, 05 Nov 2025 10:24:34 +0000_  
  Novo Nordisk‚Äôs CEO Maziar Mike Doustdar said on Wednesday he was ‚Äúnot able‚Äù to say whether the company would up its bid for Metsera any further if Pfizer re-raises its offer for ...

- **['Everybody's talking about it': Metsera bidding war grips the obesity field](https://endpoints.news/everybodys-talking-about-it-metsera-bidding-war-grips-the-obesity-field/)**  
  _Wed, 05 Nov 2025 10:00:02 +0000_  
  ATLANTA ‚Äî Novo Nordisk and Pfizer made their presence known on the first day of the annual ObesityWeek conference.

 On Tuesday, the large drugmakers escalated their bidding war for Metsera, a Phase 2 biotech creating long ...

- **[What health tech stands to gain as pharma goes DTC](https://endpoints.news/what-health-tech-stands-to-gain-as-pharma-goes-dtc/)**  
  _Tue, 04 Nov 2025 16:50:05 +0000_  
  When the Trump administration in September debuted TrumpRx.gov as part of its deal with Pfizer at ‚Äúmost favored nation‚Äù prices, my mind immediately turned to ...

- **[Incyte, Prelude ink rare blood cancer pact; Merck takes back rights to Prometheus asset](https://endpoints.news/incyte-prelude-ink-rare-blood-cancer-pact-merck-takes-back-rights-to-prometheus-asset/)**  
  _Tue, 04 Nov 2025 15:31:15 +0000_  
  Plus, news about Kaigene, Celltrion, Solid Bio, Terns Pharmaceuticals, Benitec, Pacira, AmacaThera, UCB, Basilea Pharmaceutica, Pfizer, Kura Oncology, Kyowa Kirin, Novavax, Sanofi, Syndexis and Relmada:

 üñäÔ∏è Prelude signs Incyte deal, trims pipeline: Prelude will ...

- **[Lilly and Novo near White House deal on obesity drug prices](https://endpoints.news/lilly-and-novo-near-white-house-deal-on-obesity-drugs-prices/)**  
  _Tue, 04 Nov 2025 15:19:45 +0000_  
  Eli Lilly and Novo Nordisk are preparing to announce new drug pricing deals with the White House, including for their blockbuster weight loss drugs, in return for coverage of the products under Medicare, according to ...

- **[Updated: Novo ups Metsera bid to as much as $10B in attempt to top Pfizer's new offer](https://endpoints.news/novo-ups-metsera-bid-to-as-much-as-10b-in-attempt-to-top-pfizers-new-offer/)**  
  _Tue, 04 Nov 2025 14:44:43 +0000_  
  Novo Nordisk has increased its offer for obesity biotech Metsera to as much as $10 billion, trying to outdo a new offer by Pfizer.

 Novo's latest offer is for $62.20 a ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/medtech/precision-neuroscience-inks-partnership-venture-fund-backed-spinal-cord-injury-advocates" hreflang="en">Precision Neuroscience inks partnership with venture fund backed by spinal cord injury advocates</a>](https://www.fiercebiotech.com/medtech/precision-neuroscience-inks-partnership-venture-fund-backed-spinal-cord-injury-advocates)**  
  _Nov 5, 2025 4:00am_  
  Precision Neuroscience‚Äôs brain-computer interface‚Äîa wireless device that aims to restore function to people with paralysis‚Äîis getting a boost from SCI Ventures. The fund is backed by the Christopher & Dana Reeve Foundation and other major spinal cord injury organizations.

- **[<a href="https://www.fiercebiotech.com/biotech/braveheart-bio-mission-conquer-heart-disease-market-captures-185m-series" hreflang="en">Braveheart Bio launches with mission to conquer heart disease market, capturing $185M series A</a>](https://www.fiercebiotech.com/biotech/braveheart-bio-mission-conquer-heart-disease-market-captures-185m-series)**  
  _Nov 4, 2025 4:42pm_  
  The hypertrophic-cardiomyopathy-focused biotech is led by former HI-Bio founder and CEO Travis Murdoch, M.D., while Biogen's CEO Chris Viehbacher chairs the board of directors.

- **[<a href="https://www.fiercebiotech.com/biotech/novo-drops-oncology-ambitions-early-stage-mash-prospects-ongoing-rd-shake" hreflang="en">Novo drops oncology ambitions, early-stage MASH prospects in ongoing R&amp;D shake-up</a>](https://www.fiercebiotech.com/biotech/novo-drops-oncology-ambitions-early-stage-mash-prospects-ongoing-rd-shake)**  
  _Nov 5, 2025 7:22am_  
  Novo Nordisk is winding down a range of early-stage programs for liver disease, oncology and stem cells as part of the Danish Pharma‚Äôs ambitious restructuring.

- **[<a href="https://www.fiercebiotech.com/biotech/lilly-pulls-out-cns-portion-950m-rirpk1-inhibitor-collab-rigel" hreflang="en">Lilly pulls out of CNS portion of $960M RIPK1 inhibitor collab with Rigel</a>](https://www.fiercebiotech.com/biotech/lilly-pulls-out-cns-portion-950m-rirpk1-inhibitor-collab-rigel)**  
  _Nov 5, 2025 5:27am_  
  Eli Lilly has pulled out of the central-nervous-system-focused portion of a $960 million biobucks deal centered on Rigel Pharmaceuticals‚Äô receptor-interacting serine/threonine-protein kinase 1 inhibitors.

- **[<a href="https://www.fiercebiotech.com/biotech/lilly-expands-xtalpi-collaboration-345m-antibody-development-pact" hreflang="en">Lilly expands XtalPi collaboration with $345M antibody development pact</a>](https://www.fiercebiotech.com/biotech/lilly-expands-xtalpi-collaboration-345m-antibody-development-pact)**  
  _Nov 4, 2025 2:29pm_  
  Eli Lilly is doubling down on its partnership with Chinese tech outfit XtalPi, striking a new antibody development pact that could net the AI drug discovery shop up to $345 million.

- **[<a href="https://www.fiercebiotech.com/biotech/amgen-halts-gastric-cancer-trial-after-antibody-did-not-meet-our-standard-efficacy" hreflang="en">Amgen halts gastric cancer trial after antibody 'did not meet our standard' of efficacy, exec says</a>](https://www.fiercebiotech.com/biotech/amgen-halts-gastric-cancer-trial-after-antibody-did-not-meet-our-standard-efficacy)**  
  _Nov 4, 2025 5:41pm_  
  Following a middling phase 3 readout for gastric cancer candidate bemarituzumab, Amgen has stopped another trial of the molecule.

- **[<a href="https://www.fiercebiotech.com/biotech/novo-nordisk-ceo-feels-danish-pharma-will-bag-metsera-end-pfizer-bidding-war" hreflang="en">Novo Nordisk CEO 'feels' Danish pharma will bag Metsera at end of Pfizer bidding war</a>](https://www.fiercebiotech.com/biotech/novo-nordisk-ceo-feels-danish-pharma-will-bag-metsera-end-pfizer-bidding-war)**  
  _Nov 5, 2025 4:21am_  
  Novo Nordisk‚Äôs CEO won‚Äôt comment on whether the Danish company will go even higher in its bidding war for Metsera but said the Big Pharma ‚Äúfeels this deal will be closed.

- **[<a href="https://www.fiercebiotech.com/medtech/ge-healthcare-3q-earnings-outpace-expectations-company-boosts-25-profit-forecast" hreflang="en">GE HealthCare Q3 earnings outpace expectations as company boosts profit forecast</a>](https://www.fiercebiotech.com/medtech/ge-healthcare-3q-earnings-outpace-expectations-company-boosts-25-profit-forecast)**  
  _Nov 4, 2025 11:04pm_  
  GE HealthCare¬†turned in a surprising boost in its third-quarter results driven by strong sales in its core segments, sparking the imaging giant to raise its 2025 profit guidance.

- **[<a href="https://www.fiercebiotech.com/biotech/pfizers-parade-pipeline-cuts-seagen-biontech-and-mash-programs-among-11-axed" hreflang="en">Pfizer's parade of pipeline cuts: Seagen, BioNTech and MASH programs among 11 axed</a>](https://www.fiercebiotech.com/biotech/pfizers-parade-pipeline-cuts-seagen-biontech-and-mash-programs-among-11-axed)**  
  _Nov 4, 2025 1:58pm_  
  Pfizer has axed 11 programs including two pipeline assets from its $43 billion Seagen acquisition, work on a BioNTech-partnered mRNA vaccine and a midstage MASH combo.

- **[<a href="https://www.fiercebiotech.com/medtech/qiagen-ceo-step-down-company-snaps-parse-biosciences-225-million-upfront-deal" hreflang="en">Qiagen CEO to step down as company snaps up Parse Biosciences in $225M upfront deal</a>](https://www.fiercebiotech.com/medtech/qiagen-ceo-step-down-company-snaps-parse-biosciences-225-million-upfront-deal)**  
  _Nov 4, 2025 1:55pm_  
  The news is coming thick and fast for Qiagen. As the molecular diagnostics specialist announced its third-quarter earnings, it also revealed that its long-term chief executive, Thierry Bernard, will step down while also opening its wallet for a new acquisition.

- **[<a href="https://www.fiercebiotech.com/biotech/harmony-halts-genetic-disease-program-following-ph-3-fragile-x-failure" hreflang="en">Harmony halts genetic disease program following phase 3 fragile X failure</a>](https://www.fiercebiotech.com/biotech/harmony-halts-genetic-disease-program-following-ph-3-fragile-x-failure)**  
  _Nov 4, 2025 10:57am_  
  After its cannabidiol gel candidate failed a phase 3 trial in fragile X syndrome, Harmony Biosciences has now paused development of the asset in a different genetic disease.

- **[<a href="https://www.fiercebiotech.com/biotech/publishers-note-questex-acquisition-supercharges-fierce-portfolio-conference-forum-and" hreflang="en">Publisher‚Äôs note: Questex acquisition supercharges Fierce portfolio with The Conference Forum, Versalinx Global Events</a>](https://www.fiercebiotech.com/biotech/publishers-note-questex-acquisition-supercharges-fierce-portfolio-conference-forum-and)**  
  _Nov 4, 2025 12:00pm_  
  Questex has acquired The Conference Forum and Versalinx Global Events, two highly respected organizers known for convening the leaders shaping clinical innovation, competitive intelligence, market research and the future of drug delivery.

- **[<a href="https://www.fiercebiotech.com/biotech/novo-pfizers-bidding-war-metsera-heats-supercharged-offers-obesity-biotech" hreflang="en">Novo, Pfizer's bidding war heats up with supercharged offers for Metsera</a>](https://www.fiercebiotech.com/biotech/novo-pfizers-bidding-war-metsera-heats-supercharged-offers-obesity-biotech)**  
  _Nov 4, 2025 9:55am_  
  Pfizer may have launched a multifront legal battle to prevent Metsera from heading to Novo Nordisk, but, behind the scenes, the U.S. pharma has shown some willingness to rework its own deal.

- **[<a href="https://www.fiercebiotech.com/biotech/prelude-loses-cmo-pauses-smarca2-degraders-and-bags-60m-incyte" hreflang="en">Prelude loses CMO, pauses SMARCA2 degraders and bags $60M from Incyte</a>](https://www.fiercebiotech.com/biotech/prelude-loses-cmo-pauses-smarca2-degraders-and-bags-60m-incyte)**  
  _Nov 4, 2025 8:37am_  
  The precision oncology biotech is pausing work on SMARCA2 degraders and selling a licensing option to Incyte Therapeutics.

- **[<a href="https://www.fiercebiotech.com/biotech/new-vivo-cell-therapy-biotech-blossoms-crispr-pioneer-doudnas-laboratory-82m" hreflang="en">New in vivo gene editing biotech blossoms from CRISPR pioneer Jennifer Doudna's lab with $82M</a>](https://www.fiercebiotech.com/biotech/new-vivo-cell-therapy-biotech-blossoms-crispr-pioneer-doudnas-laboratory-82m)**  
  _Nov 3, 2025 2:18pm_  
  A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed with $82 million in funding and a dual-vector approach that the company hopes can enable permanent genome editing with a‚Ä¶


## arXiv q-bio

- **[Condition-Invariant fMRI Decoding of Speech Intelligibility with Deep State Space Model](https://arxiv.org/abs/2511.01868)**  
  _Wed, 05 Nov 2025 00:00:00 -0500_  
  arXiv:2511.01868v1 Announce Type: new 
Abstract: Clarifying the neural basis of speech intelligibility is critical for computational neuroscience and digital speech processing. Recent neuroimaging studies have shown that intelligibility modulates cortical activity beyond simple acoustics, primarily in the superior tem‚Ä¶

- **[CytoNet: A Foundation Model for the Human Cerebral Cortex](https://arxiv.org/abs/2511.01870)**  
  _Wed, 05 Nov 2025 00:00:00 -0500_  
  arXiv:2511.01870v1 Announce Type: new 
Abstract: To study how the human brain works, we need to explore the organization of the cerebral cortex and its detailed cellular architecture. We introduce CytoNet, a foundation model that encodes high-resolution microscopic image patches of the cerebral cortex into highly expr‚Ä¶

- **[The impact of nonheritable variation in division rates on population growth across environments](https://arxiv.org/abs/2511.01905)**  
  _Wed, 05 Nov 2025 00:00:00 -0500_  
  arXiv:2511.01905v1 Announce Type: new 
Abstract: We analyse a series of bacterial growth models with in-built inter-individual variation in rates of cell division. We show that this variation leads to reduced population growth in favorable regimes and reduced population killing in detrimental environments. By treating‚Ä¶

- **[Epidemic Momentum](https://arxiv.org/abs/2511.01939)**  
  _Wed, 05 Nov 2025 00:00:00 -0500_  
  arXiv:2511.01939v1 Announce Type: new 
Abstract: Infectious disease outbreaks have precipitated a profusion of mathematical models. We introduce a unifying concept of "epidemic momentum" -- prevalence weighted by the capacity to infect in the future -- and use it to reveal a common underlying geometry that corresponds‚Ä¶

- **[From the RNA world to land plants: Evolutionary insights from tRNA genes](https://arxiv.org/abs/2511.01943)**  
  _Wed, 05 Nov 2025 00:00:00 -0500_  
  arXiv:2511.01943v1 Announce Type: new 
Abstract: Transfer RNAs (tRNAs) are universal adaptors of the genetic code, yet their evolutionary dynamics across photosynthetic eukaryotes remain underexplored. Here, we present the largest comparative re-analysis integrating the PlantRNA database with published data to explore‚Ä¶

- **[Reliability Assessment Framework Based on Feature Separability for Pathological Cell Image Classification under Prior Bias](https://arxiv.org/abs/2511.01953)**  
  _Wed, 05 Nov 2025 00:00:00 -0500_  
  arXiv:2511.01953v1 Announce Type: new 
Abstract: \textbf{Background and objective:} Prior probability shift between training and deployment datasets challenges deep learning--based medical image classification. Standard correction methods reweight posterior probabilities to adjust prior bias, yet their benefit is inco‚Ä¶

- **[Neural dynamics of cognitive control: Current tensions and future promise](https://arxiv.org/abs/2511.02063)**  
  _Wed, 05 Nov 2025 00:00:00 -0500_  
  arXiv:2511.02063v1 Announce Type: new 
Abstract: Cognitive control is a suite of processes that helps individuals pursue goals despite resistance or uncertainty about what to do. Although cognitive control has been extensively studied as a dynamic feedback loop of perception, valuation, and action, it remains incomple‚Ä¶

- **[In silico trials of acute ischemic stroke: predicting the total potential for improvement to patient functional outcomes](https://arxiv.org/abs/2511.02088)**  
  _Wed, 05 Nov 2025 00:00:00 -0500_  
  arXiv:2511.02088v1 Announce Type: new 
Abstract: This study uses in silico trials (ISTs) to quantify the potential for benefit due to improved recanalisation outcomes and shorter time to treatment for acute ischaemic stroke (AIS) patients. We use an IST framework to run trials on cohorts of virtual patients with early‚Ä¶

- **[DL4Proteins Jupyter Notebooks Teach how to use Artificial Intelligence for Biomolecular Structure Prediction and Design](https://arxiv.org/abs/2511.02128)**  
  _Wed, 05 Nov 2025 00:00:00 -0500_  
  arXiv:2511.02128v1 Announce Type: new 
Abstract: Computational methods for predicting and designing biomolecular structures are increasingly powerful. While previous approaches relied on physics-based modeling, modern tools, such as AlphaFold2 in CASP14, leverage artificial intelligence (AI) to achieve significantly i‚Ä¶

- **[Biological Regulatory Network Inference through Circular Causal Structure Learning](https://arxiv.org/abs/2511.02332)**  
  _Wed, 05 Nov 2025 00:00:00 -0500_  
  arXiv:2511.02332v1 Announce Type: new 
Abstract: Biological networks are pivotal in deciphering the complexity and functionality of biological systems. Causal inference, which focuses on determining the directionality and strength of interactions between variables rather than merely relying on correlations, is conside‚Ä¶

- **[Biomolecular LQR under Partial Observation](https://arxiv.org/abs/2511.02418)**  
  _Wed, 05 Nov 2025 00:00:00 -0500_  
  arXiv:2511.02418v1 Announce Type: new 
Abstract: This paper introduces a biomolecular Linear Quadratic Regulator (LQR) to investigate the design principles of gene regulatory networks. We show that for fundamental gene regulation network, the bio-controller derived from LQR theory precisely recapitulate natural networ‚Ä¶

- **[Asymptotic behavior for a general class of spreading models](https://arxiv.org/abs/2511.02437)**  
  _Wed, 05 Nov 2025 00:00:00 -0500_  
  arXiv:2511.02437v1 Announce Type: new 
Abstract: Growing literatures on epidemic and rumor dynamics show that infection and information coevolve. We present a unified framework for modeling the spread of infection and information: a general class of interaction-driven fluid-limit models expressed as coupled ODEs. The‚Ä¶

- **[Machine Learning for RNA Secondary Structure Prediction: a review of current methods and challenges](https://arxiv.org/abs/2511.02622)**  
  _Wed, 05 Nov 2025 00:00:00 -0500_  
  arXiv:2511.02622v1 Announce Type: new 
Abstract: Predicting the secondary structure of RNA is a core challenge in computational biology, essential for understanding molecular function and designing novel therapeutics. The field has evolved from foundational but accuracy-limited thermodynamic approaches to a new data-d‚Ä¶

- **[Association-sensory spatiotemporal hierarchy and functional gradient-regularised recurrent neural network with implications for schizophrenia](https://arxiv.org/abs/2511.02722)**  
  _Wed, 05 Nov 2025 00:00:00 -0500_  
  arXiv:2511.02722v1 Announce Type: new 
Abstract: The human neocortex is functionally organised at its highest level along a continuous sensory-to-association (AS) hierarchy. This study characterises the AS hierarchy of patients with schizophrenia in a comparison with controls. Using a large fMRI dataset (N=355), we ex‚Ä¶

- **[Spatial Insight: How Data-Driven Regions of Interest Selection Enhances Single-Trial P300 Classification in EEG-Based BCIs](https://arxiv.org/abs/2511.02735)**  
  _Wed, 05 Nov 2025 00:00:00 -0500_  
  arXiv:2511.02735v1 Announce Type: new 
Abstract: EEG-based Brain-Computer Interfaces (BCIs) frequently face spatial specificity limitations in detecting single-trial P300 potentials, a neurophysiological hallmark leveraged for both BCI control and neurodegenerative disease diagnostics. We present a novel framework com‚Ä¶

- **[Microbes in the Moonlight: How the Gut Microbiota Influences Sleep](https://arxiv.org/abs/2511.02766)**  
  _Wed, 05 Nov 2025 00:00:00 -0500_  
  arXiv:2511.02766v1 Announce Type: new 
Abstract: The gut microbiota has emerged as a fundamental regulator of sleep physiology, influencing neural, endocrine, and immune pathways through the gut-microbiota-brain axis (GMBA). This bidirectional communication system modulates neurotransmitter production, circadian rhyth‚Ä¶

- **[Mirror-Neuron Patterns in AI Alignment](https://arxiv.org/abs/2511.01885)**  
  _Wed, 05 Nov 2025 00:00:00 -0500_  
  arXiv:2511.01885v1 Announce Type: cross 
Abstract: As artificial intelligence (AI) advances toward superhuman capabilities, aligning these systems with human values becomes increasingly critical. Current alignment strategies rely largely on externally specified constraints that may prove insufficient against future su‚Ä¶

- **[Towards a Unified Framework for Statistical and Mathematical Modeling](https://arxiv.org/abs/2511.01960)**  
  _Wed, 05 Nov 2025 00:00:00 -0500_  
  arXiv:2511.01960v1 Announce Type: cross 
Abstract: Within the biological, physical, and social sciences, there are two broad quantitative traditions: statistical and mathematical modeling. Both traditions have the common pursuit of advancing our scientific knowledge, but these traditions have developed largely indepen‚Ä¶

- **[Predicting Microbial Interactions Using Graph Neural Networks](https://arxiv.org/abs/2511.02038)**  
  _Wed, 05 Nov 2025 00:00:00 -0500_  
  arXiv:2511.02038v1 Announce Type: cross 
Abstract: Predicting interspecies interactions is a key challenge in microbial ecology, as these interactions are critical to determining the structure and activity of microbial communities. In this work, we used data on monoculture growth capabilities, interactions with other‚Ä¶

- **[Structural Plasticity as Active Inference: A Biologically-Inspired Architecture for Homeostatic Control](https://arxiv.org/abs/2511.02241)**  
  _Wed, 05 Nov 2025 00:00:00 -0500_  
  arXiv:2511.02241v1 Announce Type: cross 
Abstract: Traditional neural networks, while powerful, rely on biologically implausible learning mechanisms such as global backpropagation. This paper introduces the Structurally Adaptive Predictive Inference Network (SAPIN), a novel computational model inspired by the principl‚Ä¶

- **[Forecasting Future Anatomies: Longitudianl Brain Mri-to-Mri Prediction](https://arxiv.org/abs/2511.02558)**  
  _Wed, 05 Nov 2025 00:00:00 -0500_  
  arXiv:2511.02558v1 Announce Type: cross 
Abstract: Predicting future brain state from a baseline magnetic resonance image (MRI) is a central challenge in neuroimaging and has important implications for studying neurodegenerative diseases such as Alzheimer's disease (AD). Most existing approaches predict future cogniti‚Ä¶

- **[STAR-VAE: Latent Variable Transformers for Scalable and Controllable Molecular Generation](https://arxiv.org/abs/2511.02769)**  
  _Wed, 05 Nov 2025 00:00:00 -0500_  
  arXiv:2511.02769v1 Announce Type: cross 
Abstract: The chemical space of drug-like molecules is vast, motivating the development of generative models that must learn broad chemical distributions, enable conditional generation by capturing structure-property representations, and provide fast molecular generation. Meeti‚Ä¶

- **[Modulation of metastable ensemble dynamics explains the inverted-U relationship between tone discriminability and arousal in auditory cortex](https://arxiv.org/abs/2404.03902)**  
  _Wed, 05 Nov 2025 00:00:00 -0500_  
  arXiv:2404.03902v3 Announce Type: replace 
Abstract: Past work has reported inverted-U relationships between arousal and auditory task performance, but the underlying neural network mechanisms remain unclear. To make progress, we recorded auditory cortex activity from behaving mice during passive tone presentation and‚Ä¶

- **[Computational strategies for cross-species knowledge transfer](https://arxiv.org/abs/2408.08503)**  
  _Wed, 05 Nov 2025 00:00:00 -0500_  
  arXiv:2408.08503v2 Announce Type: replace 
Abstract: Research organisms provide invaluable insights into human biology and diseases, serving as essential tools for functional experiments, disease modeling, and drug testing. However, evolutionary divergence between humans and research organisms hinders effective knowle‚Ä¶

- **[Gradient GA: Gradient Genetic Algorithm for Drug Molecular Design](https://arxiv.org/abs/2502.09860)**  
  _Wed, 05 Nov 2025 00:00:00 -0500_  
  arXiv:2502.09860v2 Announce Type: replace 
Abstract: Molecular discovery has brought great benefits to the chemical industry. Various molecule design techniques are developed to identify molecules with desirable properties. Traditional optimization methods, such as genetic algorithms, continue to achieve state-of-the-‚Ä¶

- **[Scalable and Cost-Efficient de Novo Template-Based Molecular Generation](https://arxiv.org/abs/2506.19865)**  
  _Wed, 05 Nov 2025 00:00:00 -0500_  
  arXiv:2506.19865v2 Announce Type: replace 
Abstract: Template-based molecular generation offers a promising avenue for drug design by ensuring generated compounds are synthetically accessible through predefined reaction templates and building blocks. In this work, we tackle three core challenges in template-based GFlo‚Ä¶

- **[Quantifying AI-to-Clinical Translation: The Algorithm-to-Outcome Concordance (AOC) Framework](https://arxiv.org/abs/2510.26685)**  
  _Wed, 05 Nov 2025 00:00:00 -0500_  
  arXiv:2510.26685v2 Announce Type: replace 
Abstract: Background: Despite high in-silico performance (AUC >0.80), 85% of AI cancer biomarkers fail clinical translation, exposing a critical algorithm-to-outcome gap. Methods: We introduce the Algorithm-to-Outcome Concordance (AOC) framework, integrating model accuracy (A‚Ä¶

- **[Cross-modal Diffusion Modelling for Super-resolved Spatial Transcriptomics](https://arxiv.org/abs/2404.12973)**  
  _Wed, 05 Nov 2025 00:00:00 -0500_  
  arXiv:2404.12973v3 Announce Type: replace-cross 
Abstract: The recent advancement of spatial transcriptomics (ST) allows to characterize spatial gene expression within tissue for discovery research. However, current ST platforms suffer from low resolution, hindering in-depth understanding of spatial gene expression. S‚Ä¶

- **[Desynchronization Index: a New Connectivity Approach for Exploring Epileptogenic Networks](https://arxiv.org/abs/2408.16347)**  
  _Wed, 05 Nov 2025 00:00:00 -0500_  
  arXiv:2408.16347v5 Announce Type: replace-cross 
Abstract: Objective: This work presents a new computational framework to assist neurophysiologists in Stereoelectroencephalography (SEEG) analysis, with the goal of improving the definition of the Epileptogenic Zone (EZ) in patients with drug-resistant epilepsy. Methods‚Ä¶

- **[Surrogate modeling of Cellular-Potts Agent-Based Models as a segmentation task using the U-Net neural network architecture](https://arxiv.org/abs/2505.00316)**  
  _Wed, 05 Nov 2025 00:00:00 -0500_  
  arXiv:2505.00316v4 Announce Type: replace-cross 
Abstract: The Cellular-Potts model is a powerful and ubiquitous framework for developing computational models for simulating complex multicellular biological systems. Cellular-Potts models (CPMs) are often computationally expensive due to the explicit modeling of intera‚Ä¶

- **[Contrastive Consolidation of Top-Down Modulations Achieves Sparsely Supervised Continual Learning](https://arxiv.org/abs/2505.14125)**  
  _Wed, 05 Nov 2025 00:00:00 -0500_  
  arXiv:2505.14125v2 Announce Type: replace-cross 
Abstract: Biological brains learn continually from a stream of unlabeled data, while integrating specialized information from sparsely labeled examples without compromising their ability to generalize. Meanwhile, machine learning methods are susceptible to catastrophic‚Ä¶

- **[Intermittent localization and fast spatial learning by non-Markov random walks with decaying memory](https://arxiv.org/abs/2509.01806)**  
  _Wed, 05 Nov 2025 00:00:00 -0500_  
  arXiv:2509.01806v3 Announce Type: replace-cross 
Abstract: Random walks on lattices with preferential relocation to previously visited sites provide a simple framework for modeling the displacements of animals and humans. When the lattice contains a few impurities or resource sites where the walker spends more time on‚Ä¶
